Abstract
The ability to elicit broadly neutralizing antibody responses against HIV-1 is a crucial goal for a prophylactic HIV-1 vaccine. Here, we discuss the difficulties of achieving broad HIV-1 neutralization in the context of both the effective annual human influenza virus vaccine and the need to develop a pandemic influenza vaccine. Immunogen-design strategies are underway to target functionally conserved regions of the HIV-1 envelope glycoproteins, and similar strategies might be applicable to pandemic influenza virus vaccine development. Efforts to develop broadly neutralizing vaccines against either HIV-1 or influenza virus might establish a paradigm for future vaccines against highly variable pathogens.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, N.I.H., Intramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
AIDS Vaccines / immunology*
-
Animals
-
Antibodies, Viral / blood*
-
Drug Design
-
HIV Antibodies / blood*
-
HIV Infections / immunology
-
HIV Infections / prevention & control
-
HIV-1 / immunology*
-
Humans
-
Influenza A virus / immunology
-
Influenza Vaccines / immunology*
-
Influenza, Human / immunology
-
Influenza, Human / prevention & control
-
Neutralization Tests
-
Viral Envelope Proteins / immunology
-
env Gene Products, Human Immunodeficiency Virus / immunology
Substances
-
AIDS Vaccines
-
Antibodies, Viral
-
HIV Antibodies
-
Influenza Vaccines
-
Viral Envelope Proteins
-
env Gene Products, Human Immunodeficiency Virus